1.374
price down icon1.43%   -0.026
 
loading
Schlusskurs vom Vortag:
$1.40
Offen:
$1.4
24-Stunden-Volumen:
561.21K
Relative Volume:
0.18
Marktkapitalisierung:
$1.09B
Einnahmen:
$711.41M
Nettoeinkommen (Verlust:
$-133.73M
KGV:
-7.2316
EPS:
-0.19
Netto-Cashflow:
$-199.99M
1W Leistung:
+3.76%
1M Leistung:
+6.98%
6M Leistung:
-6.12%
1J Leistung:
-5.48%
1-Tages-Spanne:
Value
$1.37
$1.41
1-Wochen-Bereich:
Value
$1.325
$1.43
52-Wochen-Spanne:
Value
$1.21
$2.035

Opko Health Inc Stock (OPK) Company Profile

Name
Firmenname
Opko Health Inc
Name
Telefon
305-575-4181
Name
Adresse
4400 BISCAYNE BLVD., MIAMI, FL
Name
Mitarbeiter
2,997
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-07
Name
Neueste SEC-Einreichungen
Name
OPK's Discussions on Twitter

Vergleichen Sie OPK mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Diagnostics & Research icon
OPK
Opko Health Inc
1.375 1.06B 711.41M -133.73M -199.99M -0.19
Diagnostics & Research icon
TMO
Thermo Fisher Scientific Inc
427.06 160.56B 42.90B 6.52B 6.72B 17.05
Diagnostics & Research icon
DHR
Danaher Corp
195.73 141.52B 23.82B 3.77B 4.90B 5.15
Diagnostics & Research icon
IDXX
Idexx Laboratories Inc
530.12 42.74B 3.93B 894.97M 837.70M 10.82
Diagnostics & Research icon
A
Agilent Technologies Inc
116.24 34.11B 6.63B 1.17B 1.19B 4.05
Diagnostics & Research icon
IQV
Iqvia Holdings Inc
185.99 27.70B 15.50B 1.33B 2.16B 7.34

Opko Health Inc Stock (OPK) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-04-25 Eingeleitet JP Morgan Neutral
2023-06-29 Hochstufung Barrington Research Mkt Perform → Outperform
2022-12-15 Eingeleitet H.C. Wainwright Buy
2022-01-24 Herabstufung Barrington Research Outperform → Mkt Perform
2021-06-21 Eingeleitet Ladenburg Thalmann Buy
2019-11-25 Eingeleitet Piper Jaffray Overweight
2018-03-02 Herabstufung JP Morgan Neutral → Underweight
2017-09-14 Herabstufung JP Morgan Overweight → Neutral
2016-06-21 Bestätigt Standpoint Research Buy
2016-06-03 Eingeleitet Standpoint Research Buy
2016-03-31 Bestätigt Barrington Research Outperform
2015-10-16 Eingeleitet JP Morgan Overweight
2015-09-11 Herabstufung Jefferies Buy → Hold
2015-03-03 Herabstufung Oppenheimer Outperform → Perform
2014-05-12 Bestätigt Oppenheimer Outperform
2014-03-14 Eingeleitet Oppenheimer Outperform
2013-11-13 Bestätigt Ladenburg Thalmann Buy
2013-05-30 Bestätigt Ladenburg Thalmann Buy
2012-10-22 Eingeleitet Barrington Research Outperform
2011-12-01 Bestätigt Ladenburg Thalmann Buy
2011-07-14 Eingeleitet Ladenburg Thalmann Buy
Alle ansehen

Opko Health Inc Aktie (OPK) Neueste Nachrichten

pulisher
07:20 AM

What drives OPKO Health Inc. stock priceConsistently high yield - jammulinksnews.com

07:20 AM
pulisher
03:16 AM

OPKO Health Inc. Stock Analysis and ForecastDynamic investment opportunities - jammulinksnews.com

03:16 AM
pulisher
Jul 21, 2025

What analysts say about OPKO Health Inc. stockSkyrocketing returns - Autocar Professional

Jul 21, 2025
pulisher
Jul 20, 2025

Is OPKO Health Inc. a good long term investmentOutstanding yields - Autocar Professional

Jul 20, 2025
pulisher
Jul 14, 2025

OPKO Health (NASDAQ:OPK) Stock Rating Upgraded by LADENBURG THALM/SH SH - MarketBeat

Jul 14, 2025
pulisher
Jul 14, 2025

OPKO Health, Inc. (NASDAQ:OPK) Receives $2.75 Consensus Price Target from Analysts - MarketBeat

Jul 14, 2025
pulisher
Jul 11, 2025

H.C. Wainwright Reiterates a Buy Rating on Opko Health (OPK), Keeps the PT at $3 - MSN

Jul 11, 2025
pulisher
Jul 11, 2025

Opko Health (OPK) Has a New Rating from Ladenburg Thalmann & Co. - The Globe and Mail

Jul 11, 2025
pulisher
Jul 11, 2025

Capital Advisors Inc. OK Increases Holdings in OPKO Health, Inc. (NASDAQ:OPK) - MarketBeat

Jul 11, 2025
pulisher
Jul 08, 2025

OPKO Health and Entera Bio Announce Abstract on PK/PD of - GlobeNewswire

Jul 08, 2025
pulisher
Jul 08, 2025

OPKO Health and Entera Bio abstract selected for ESPEN Congress - StreetInsider

Jul 08, 2025
pulisher
Jul 08, 2025

OPKO Health and Entera Bio Announce Abstract on PK/PD of Oral GLP-2 Tablet for the Treatment of Short Bowel Syndrome Selected for 2025 ESPEN Congress - Yahoo Finance

Jul 08, 2025
pulisher
Jul 08, 2025

Breakthrough: First-Ever Oral Tablet Could Replace Daily Injections for Short Bowel Syndrome Treatment - Stock Titan

Jul 08, 2025
pulisher
Jul 04, 2025

Investor Network: OPKO Health, Inc. to Host Earnings Call - ACCESS Newswire

Jul 04, 2025
pulisher
Jun 30, 2025

OPKO Health (OPK) to Present OPK-88006 Data at ENDO 2025 - MSN

Jun 30, 2025
pulisher
Jun 30, 2025

OPKO Health's Russell 2000 Defensive Index Inclusion: A Catalyst for Strategic Revaluation - AInvest

Jun 30, 2025
pulisher
Jun 29, 2025

10 Best Healthcare Penny Stocks to Buy According to Analysts - Insider Monkey

Jun 29, 2025
pulisher
Jun 25, 2025

OPKO and Entera to present data on oral obesity treatment at ENDO 2025 - Investing.com Nigeria

Jun 25, 2025
pulisher
Jun 25, 2025

OPKO Health and Entera Bio Abstract for First-in-Class Dual GLP-1/Glucagon Tablet Candidate for Patients with Obesity and Metabolic Disorders Selected for Presentation at the ENDO 2025 Annual Meeting - OPKO Health, Inc.

Jun 25, 2025
pulisher
Jun 24, 2025

Piper Sandler Reiterates a Buy Rating on Opko Health (OPK) With a $3 PT - Yahoo Finance

Jun 24, 2025
pulisher
Jun 23, 2025

13 Best Long-Term Penny Stocks to Buy According to Analysts - Insider Monkey

Jun 23, 2025
pulisher
Jun 18, 2025

Shareholders in OPKO Health (NASDAQ:OPK) have lost 51%, as stock drops 6.5% this past week - simplywall.st

Jun 18, 2025
pulisher
Jun 14, 2025

Here's Why You Should Retain OPKO Health Stock in Your Portfolio - MSN

Jun 14, 2025
pulisher
Jun 13, 2025

Quote - OPKO Health, Inc.

Jun 13, 2025
pulisher
Jun 13, 2025

Bone Cancer Drugs Market Set to Witness Significant Growth - openPR.com

Jun 13, 2025
pulisher
Jun 13, 2025

Bank of America Corp DE Has $855,000 Stock Holdings in OPKO Health, Inc. (NASDAQ:OPK) - MarketBeat

Jun 13, 2025
pulisher
Jun 11, 2025

OPKO Health: Strong Pipeline Of Drugs, But Not Rushing To Buy (NASDAQ:OPK) - Seeking Alpha

Jun 11, 2025
pulisher
Jun 09, 2025

ModeX assembles advisory board for antibody development By Investing.com - Investing.com India

Jun 09, 2025
pulisher
Jun 09, 2025

ModeX assembles advisory board for antibody development - Investing.com

Jun 09, 2025
pulisher
Jun 09, 2025

OPKO Health's ModeX Therapeutics Announces Formation of Scientific Advisory Board with Leaders at the Forefront of Immunology and Oncology Drug Development - The Manila Times

Jun 09, 2025
pulisher
Jun 09, 2025

OPKO Health's (OPK) ModeX Therapeutics Forms Scientific Advisory Board - StreetInsider

Jun 09, 2025
pulisher
Jun 09, 2025

OPKO Health’s ModeX Therapeutics Announces Formation of Scientific Advisory Board with Leaders at the Forefront of Immunology and Oncology Drug Development - GlobeNewswire

Jun 09, 2025
pulisher
Jun 09, 2025

OPKO Health’s ModeX Therapeutics Announces Formation of Scientific Advisory Board with Leaders at the Forefront of Immunology and Oncology Drug Development - GlobeNewswire Inc.

Jun 09, 2025
pulisher
Jun 06, 2025

Nuveen Asset Management LLC Boosts Holdings in OPKO Health, Inc. (NASDAQ:OPK) - MarketBeat

Jun 06, 2025
pulisher
Jun 05, 2025

BNP Paribas Financial Markets Cuts Position in OPKO Health, Inc. (NASDAQ:OPK) - MarketBeat

Jun 05, 2025
pulisher
Jun 04, 2025

OPKO Health, Inc. (NASDAQ:OPK) Shares Purchased by Two Sigma Investments LP - MarketBeat

Jun 04, 2025
pulisher
Jun 04, 2025

Peptide Therapeutics Market Growth Set to Surge Significantly - openPR.com

Jun 04, 2025

Finanzdaten der Opko Health Inc-Aktie (OPK)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Opko Health Inc-Aktie (OPK) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
FROST PHILLIP MD ET AL
CEO & Chairman
Apr 08 '25
Buy
1.48
125,000
184,650
213,876,448
FROST PHILLIP MD ET AL
CEO & Chairman
Apr 01 '25
Buy
1.65
100,000
164,850
213,751,448
FROST PHILLIP MD ET AL
CEO & Chairman
Mar 28 '25
Buy
1.70
150,000
254,385
213,651,448
FROST PHILLIP MD ET AL
CEO & Chairman
Mar 17 '25
Buy
1.74
200,000
347,820
213,501,448
FROST PHILLIP MD ET AL
CEO & Chairman
Feb 28 '25
Buy
1.71
67,434
115,312
213,301,448
FROST PHILLIP MD ET AL
CEO & Chairman
Jan 28 '25
Buy
1.47
47,537
70,060
213,234,014
FROST PHILLIP MD ET AL
CEO & Chairman
Jan 17 '25
Buy
1.47
150,000
220,425
213,186,477
FROST PHILLIP MD ET AL
CEO & Chairman
Jan 15 '25
Buy
1.48
500,000
740,850
213,036,477
FROST PHILLIP MD ET AL
CEO & Chairman
Dec 13 '24
Buy
1.59
125,000
199,375
212,536,477
FROST PHILLIP MD ET AL
CEO & Chairman
Dec 11 '24
Buy
1.56
500,000
781,050
212,411,477
diagnostics_research WAT
$290.12
price up icon 3.16%
$141.87
price up icon 1.13%
diagnostics_research DGX
$176.16
price up icon 5.36%
diagnostics_research LH
$253.58
price up icon 4.60%
diagnostics_research MTD
$1,215.79
price up icon 4.54%
diagnostics_research IQV
$184.84
price up icon 16.50%
Kapitalisierung:     |  Volumen (24h):